Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL.
Baliakas, P, Hadzidimitriou, A, Sutton, L et al.
Key Points:
Authors report initial results on prevalence and prognostic impact of recurrent gene mutations.
3185 patients included; mutations in BIRC3 and MYD55 found in 2.7% and 2.2% respectively; BIRC3 mutations were also significantly (p<0.05) more frequent in cases with unmutated IGHV genes (U-CLL), del (11q) and trisomy 12.
Three gene (TP53, NOTCH1 and SF3B1) mutations significantly associated with Binet stages B/C, shorter lymphocyte doubling time and U-CLL.
Mmutations in NOTCH1 or SF3B1 and p53ab significantly associated with shorter time-to-first treatment.
Implications:
- Prevalence and prognostic impact of novel gene mutations recurrent in CLL.
View the original abstract on the ASH website.
